|
CNBC'S MOST SHARED
- Five States That Will Lead US Out of Recession
- Commercial Real Estate Wreck Looms For Regional Banks
- Other People Are Weirder Than We Are
- John S. Barry, Main Force Behind WD-40, Dies at 84
- Warren Buffett Cuts Stake in Moody's By Almost 17%
- Trading Microsoft Into Earnings
- Is Amazon Going On A Shopping Spree?
- The World’s Most Beautiful Currencies
- Microsoft Says Windows 7 Ready for October Launch
- 3M Profit Smashes Forecasts, Health Care Contributes
- AT&T Beats Profit Forecast, Wireless Growth Strong
- Wyeth Beats Street Target, Ups Guidance
- Credit Suisse Quarterly Net Profit Beats Forecasts
- Philip Morris Tops View, Raises Full-Year Guidance
- GM to Continue Talks with Magna, RHJ on Opel Bids
- ST-Ericsson Loss Widens, Bids for Nortel Assets
- International Bank Lending Shrinks by $6 Trillion: BIS
- Porsche Axes CEO, Sets Stage for VW Merger
- Warren Buffett Cuts Stake in Moody's By Almost 17%
- You Can't Go Wrong With 'Best of Breed' Stocks: Analyst
- eBay May Have Finally Bottomed
- Pitts: New Rx For New FDA Chief
- NASDAQ's Biggest Winners in 11-Day Streak
- Brooklyn Decker Talks iPhone And We Take Photos
- The Power Of The Compliment
- Your Best Tech Stock Plays: Strategists
- Why Analysts Seem to Be Getting It Wrong
European shared closed lower on Friday, and notched up a fourth straight week of losses on worries about corporate earnings and the pace of economic recovery, with drugmakers and banks suffering most.
The FTSEurofirst 300 index of top European shares fell 1.1 percent to a provisional close of 814.43 points, its lowest close in more than 10 weeks.
Over the week, it fell 3.3 percent, but is still up more than 26 percent from the record low it hit in early March.
Drugmakers were among the biggest losers. GlaxoSmithKline, Novartis, Shire, AstraZeneca, Roche and Sanofi-Aventis fell between 0.7 and 2.5 percent.
Next week, Novartis will be the first of the sector's major players to report second-quarter earnings.
Pharmas initially fared better in the downturn than other sectors but has begun to underperform, and bleak prospects of more competition, problems getting new drugs to market and cheaper medicines are looming on investors' radars.
U.S. consumer sentiment soured in early July, slipping to its weakest since March, when confidence in the financial sector and economy were at a low ebb, the Reuters/University of Michigan Surveys of Consumers showed on Friday.
Consumers' escalating concerns about an extended economic downturn, job security and erosion of wealth were the main factors depressing sentiment, the survey said.
Its preliminary index of confidence for July fell to a reading of 64.6 from the final reading for June of 70.8.
"The Michigan number was a bit of a disappointment," said Mike Lenhoff, chief strategist at Brewin Dolphin Securities, in London.
"But second-quarter earnings have become more important than ever, as the market is focused on recovery. Expectations have been revised down so much, that earnings may end up surprising some people on the upside."







